MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12882-026-04860-x

Медицинская библиотека · BMC nephrology · 2026

Roxadustat induced fetal hemoglobin in anemic CKD patients: a dual-center real-world observational cohort study.

Gou Wanling, Chen Maoshan, Li Zhuoying, Tan Chengning, Hu Lanyue, Wang Xiaojie, Jiang Yangzhou, Yu Teng, Li Xiaoliang, Yin Xiaoting, Xiao Yanni, Xiang Lixin, Duan Wenbing, Ran Qian, Li Zhongjun, Chen Li

СтатьяНаблюдательное исследованиеМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Induction of fetal hemoglobin (HbF) expression is a promising therapeutic approach for hemoglobinopathies. HbF is primarily regulated by hypoxia-inducible factor (HIF). Roxadustat, an oral HIF prolyl hydroxylase inhibitor (HIF-PHI), is utilized in the treatment of chronic kidney disease (CKD) patients with anemia. Its capacity to induce HbF has been demonstrated in cell and animal models, but not in humans.

METHODS

In this dual-center, prospective, real-world, non-randomized observational cohort study, we initially enrolled 85 anemic CKD patients receiving distinct anti-anemia treatments. Following post hoc exclusion of participants with insufficient follow-up data, we analyzed the data of 52 patients, comprising those in the oral Roxadustat group (n = 27) and the subcutaneous erythropoiesis-stimulating agent (ESA) group (n = 25). HbF levels were monitored every four weeks by measuring the percentage of HbF-positive red blood cells (F-cells) and mean corpuscular fetal hemoglobin (MCHbF).

RESULTS

Roxadustat administration showed progressive elevation of HbF levels, however, the ESA group exhibited only minor nonprogressive HbF fluctuations throughout the observation period. Significant differences in the increase of F-cells percentage and MCHbF between the two groups were observed at week 4 and amplified at week 8 and 12. Only one patient in the Roxadustat group exhibited clinically significant hypothyroidism requiring levothyroxine replacement. Safety monitoring was limited to clinically evident events reported during routine visits; consequently, subclinical abnormalities or mild adverse events were not systematically documented.

CONCLUSION

Our study suggested that Roxadustat has the potential to induce HbF expression in anemic CKD patients. STUDY REGISTRATION: The study was registered retrospectively in the Chinese Clinical Trial Registry (ChiCTR, https://www.chictr.org.cn) under the identifier ChiCTR2500096786 on February 6, 2025.

Для цитирования: Gou Wanling, Chen Maoshan, Li Zhuoying, Tan Chengning, Hu Lanyue, Wang Xiaojie, Jiang Yangzhou, Yu Teng, Li Xiaoliang, Yin Xiaoting, Xiao Yanni, Xiang Lixin, Duan Wenbing, Ran Qian, Li Zhongjun, Chen Li. Roxadustat induced fetal hemoglobin in anemic CKD patients: a dual-center real-world observational cohort study.. BMC nephrology. 2026. DOI: 10.1186/s12882-026-04860-x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.